| Literature DB >> 31852505 |
Zahra Rezaei1,2, Nick Van Reet3, Gholamreza Pouladfar2, Vera Kühne3, Amin Ramezani4, Bahador Sarkari5,6, Bahman Pourabbas7, Philippe Büscher3.
Abstract
BACKGROUND: Kinesin-related gene diversity among strains and species of Leishmania may impact the sensitivity and specificity of serodiagnostic tests for visceral leishmaniasis (VL).Entities:
Keywords: Eukaryotic expression; Leishmania; Serodiagnosis; Visceral leishmaniasis; rK39
Mesh:
Substances:
Year: 2019 PMID: 31852505 PMCID: PMC6921591 DOI: 10.1186/s13071-019-3839-3
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Primers used in the PCR
| Primer | Configuration | Sequence (5′–3′) |
|---|---|---|
| XbaI-rK39 F | Secreted | |
| NcoI-rK39 F | Cytoplasmic | |
| KpnI-rK39 R | Hexa-histag |
Notes: Nucleotides in italics, sequence complementary to pLEXSY-hyg2; nucleotides in bold, restriction site; nucleotides underlined, K39 sequence from GenBank (L07879)
Fig. 1PCR amplified kinesin-like gene fragments from promastigotes of the Iranian L. infantum isolate MCAN/IR/14/M14 using XbaI-rK39F and KpnI-rK39R primers. Lanes 1–4: PCR products generated at annealing temperature of 64 °C, 65 °C, 66 °C and 67 °C, respectively; Lane M: GeneRuler 100 bp Plus DNA (Thermo Fisher Scientific)
Fig. 2Amino acid alignment of the corresponding fragment of the translated GenBank reference sequence L07879 [13] with the two longest sequences from K39 clones from MCAN/IR/14/M14 obtained in pLEXSY-hyg2: MCAN14/47 (GenBank: MN585730) and MCAN14-22 (GenBank: MN585731)
Fig. 3SDS-PAGE (a) and Western blot (b) showing the protein composition of the different fractions collected from L. tarentolae clone pLEXSY-hyg2-MCAN14/47, before and after the purification on the Ni-NTA. a Lane 1: whole cell lysate; Lane 2: flow-through from Ni-NTA column; Lanes 3 and 4: wash fractions; Lanes 5–8: elution fractions; Lane 9: recombinant His-tagged H2B (positive control); Lane 10: 11–245 kDa protein marker. b Lanes 1–6: elution fractions; Lane 7: flow-through; Lane 8: whole cell lysate; Lane 9: 11–245 kDa protein marker
Fig. 4Receiver operator characteristic curves constructed from ELISA results. a ROC curve obtained with sera from VL patients and all the samples. b ROC curve obtained with sera from VL patients and non-endemic controls